Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer
Abstract Non-small cell lung cancer (NSCLC) shows high drug resistance and leads to low survival due to the high level of mutated Tumor Protein p53 (TP53). Cisplatin is a first-line treatment option for NSCLC, and the p53 mutation is a major factor in chemoresistance. We demonstrate that cisplatin c...
Zapisane w:
| Główni autorzy: | , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Nature Portfolio
2024-03-01
|
| Seria: | Nature Communications |
| Dostęp online: | https://doi.org/10.1038/s41467-024-47080-3 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|